Fluconazole prophylaxis against invasive candidiasis in very low and extremely low birth weight preterm neonates: a systematic review and meta-analysis

Mahmoud Robati Anaraki, DDS, MSc1,2, Masoud Nouri-Vaskeh, MD3, Shahram Abdoli Oskoei, MD, MSc4
1Dental and Periodontal Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 2Department of Prosthodontics, Dental School, Tabriz University of Medical Sciences, Tabriz, Iran; 3Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 4Pediatric Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Background: Evidence shows that fluconazole prophylaxis is an effective treatment against invasive fungal infections in preterm neonates, however, the most efficient schedule of fluconazole prophylaxis for the colonization and mortality of invasive candidiasis (IC) is unknown.

Purpose: This systematic review and meta-analysis aimed to assess the efficiency of different prophylactic fluconazole schedules in controlling IC colonization, infection, and mortality in very low birth weight (VLBW) and extremely low birth weight (ELBW) infants in neonatal intensive care units.

Methods: We searched the PubMed, Scopus, Embase, and Cochrane databases using the keywords “candida,” “invasive candidiasis,” “IC,” “fluconazole prophylaxis,” “preterm infants,” “very low birth weight infants,” “VLBW,” “extremely low birth weight,” and “ELBW.”

Results: Mortality was significantly decreased in a meta-analysis of studies using different fluconazole prophylaxis regimens. The meta-analysis also indicated a significant decrease in the incidence of IC-associated mortality in ELBW infants using the same fluconazole prophylaxis schedules.

Conclusion: Future studies should explore the effectiveness of other different fluconazole prophylaxis schedules on IC colonization, infection, and mortality.

Key words: Preterm infants, Very low birth weight, Extremely low birth weight, Fluconazole, Invasive candidiasis

Key message
- Mortality is decreased significantly in meta-analysis of studies in different regimen of fluconazole prophylaxis.
- Significant decrease was seen in incidence of invasive candidiasis-associated mortality in extremely low birth weight infants in same schedules of prophylaxis.
- More studies required to relief the concerns.

Introduction

Invasive candidiasis (IC) in very low birth weight (VLBW) infants can be fatal and often results in neurodevelopmental impairment. IC as a fungal infection in the blood and other sterile body liquids is a frequent cause of mortality in VLBW infants. Despite antifungal treatment, patients with IC have a mortality rate of 20%–60%, while surviving babies may develop neurodevelopmental impairments.1,2)

The extensive involvement of IC in the neonatal intensive care unit (NICU) is related to immaturity of the immune system and other risk factors including prematurity, intratracheal intubation or catheterization, surgery, prevention of infection, and the administration of antibiotics and corticosteroids. Fungal infection in neonates often originates from Candida albicans and on recently Candida parapsilosis.1-7) Successive control of candidiasis in infants requires proper and effective antifungal and supportive treatments to prevent IC.1,4) A progressive fluconazole prophylaxis showed efficiency, immunity, and prolonged positive neurodevelopmental results in NICU infants in an evaluation at 2 years of age, with more than 15% of the risk consisting of problems such as profound bilateral hearing loss, severe cognitive delay, and severe cerebral palsy.8-14) In addition, antifungal prophylaxis reduces the incidence of mortality due to invasive fungal infection in VLBW infants.15)

A meta-analysis of 5 randomized clinical trials (RCTs) demonstrated that prophylaxis consisting of different 42-day fluconazole treatment schedules effectively controlled mortality compared to 28-day treatment.16) Several studies compared different fluconazole doses and administration schedules to identify the best treatment option10,17,18); although it remains unknown which schedule and treatment dose is most efficient for controlling colonization (implantation and growth of a microorganism on a host), mortality (as the quality being subject to death), and IC in VLBW infants.19)
evaluate the different regimens to identify the most efficient fluconazole prophylaxis schedule against IC in VLBW infants.

Methods

1. Search strategy

This systematic review and meta-analysis was conducted according to the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines. Two investigators independently searched the PubMed, Scopus, Embase, and Cochrane databases for all eligible studies. Forward citation tracking was also performed to identify additional relevant studies. The keywords used in the search were “invasive candidiasis,” “candida,” “fluconazole prophylaxis,” “preterm infants,” “very low birth weight infants,” “VLBW,” “extremely low birth weight,” and “ELBW.” Two researchers independently searched for all relevant English articles published between 2001 and January 2018 and then performed forward citation tracking. The selected studies were RCTs and cohort studies with historical controls that explored the effect of prophylaxis with fluconazole in first 24 hours of life in VLBW infants on the incidence of IC colonization and mortality rates versus placebo or without fluconazole prophylaxis. Methodological quality was assessed using standardized methods, for instance, the Newcastle-Ottawa Scale was used to assess cohort studies. The results were compared, and any questions or discrepancies were resolved through iteration and consensus.

2. Data extraction

The following data were extracted from the retrieved studies: baseline characteristics (authors, year of publication, number of patients, birth weight, and antifungal therapy characteristics) and outcomes of interest (incidence of proven IC, colonization, overall mortality, and IC-related mortality). A total of 174 articles were selected: 43 from PubMed, 32 from Scopus, 15 from Embase, 21 from Cochrane, and 63 from the manual search. Among the 174 articles, 84 were duplicated and 90 remained. Of them, 74 were excluded, including 29 reviews and expert commentary, 9 epidemiology of IC articles, 7 case reports, 5 case-control articles, 3 drug schedules and hygiene in NICU, 9 studies of pharmacokinetics of antifungal drugs, and 12 with unrelated titles from original articles describing antifungal
prophylaxis use in VLBW infants. Sixteen studies were eligible for comparative evaluation (Fig. 1). As mentioned in Fig. 1, 3 studies that postponed starting prophylaxis more than 24 hours after birth were excluded. The primary outcome of this meta-analysis was mortality, while the secondary outcomes were colonization and IC.

3. Included studies
For assessing the incidence of IC and mortality in VLBW and extremely low birth weight (ELBW) infants, fluconazole prophylaxis regimens used in 16 studies were reviewed. The study characteristics are mentioned in Table 1. All schedules consisted of 3- or 6-mg/kg fluconazole mostly for 4–6 weeks in 7 schedules for infants with a birth weight less than 1,500 g.

IC and/or mortality with or without colonization and IC-associated mortality were evaluated in 4,486 subjects in 9 RCTs and 8 cohort studies with 1,358 and 3,128 subjects, respectively, to compare the effect of prophylaxis with fluconazole and treatment with placebo or no prophylaxis in ELBW and VLBW infants. Table 2 shows the outcomes in addition the author’s name and year of the publication of every study. The meta-analysis included 4 groups of 2 or 3 studies each that had same study protocol, dose, frequency, and duration.

4. Statistical analyses
In every study, the risk ratios (RRs) for colonization, IC, IC-associated mortality, and mortality were determined by meta-analysis and the pooled RR was calculated to assess outcomes. The F statistics and Cochrane Q were derived to estimate the fraction of variability between study RRs due to heterogeneity rather than chance. F values of 25–75 and F >75 were considered middle and high heterogeneity, respectively. In cases of heterogeneity, the random-effects model was used to determine the overall effect size. Egger regression test and a funnel plot were used to assess publication bias. Statistical analyses were performed using comprehensive meta-analysis ver. 2.0 software (Biostat Inc., Englewood, CO, USA), and P values <0.05 were considered significant.

Results

1. IC-associated mortality
Mortality with or without IC was surveyed of the 7 RCTs and 9 cohort studies. Six studies showed significantly decreased mortality and/or IC-associated mortality in the prophylaxis groups. Rueda et al. showed less IC-associated mortality in relation to all-cause death by prophylaxis year (P<0.05), while most deaths occurred in infants less than 1,000 g and neonates born at less than 31-week gestation. Kirpal et al. reported that IC-associated mortality was significantly decreased with prophylaxis use in infants (Table 2). Regardless of schedule, the current meta-analysis showed that prophylaxis with fluconazole can significantly decrease the IC-associated mortality of VLBW infants weighing ≤1,000 g (P=0.011) (RR, 0.068; 95% confidence interval [CI], 0.009–0.543) (Figs. 2, 3) with different regimens and the administration of 3-mg fluconazole every 3 days in weeks 1 and 2, then every 2 days in weeks 3 and 4, and every day in weeks 5 and 6 decreased mortality rates significantly (P=0.023) (RR, 0.780; 95% CI, 0.629–0.966). The heterogeneity was not significant in these 2 outcomes as shown in Table 3 (group 2 for mortality: Q=3.20, degrees of freedom [df]=2, P=0.202, F=37.486; group 2 for IC-associated mortality: Q=0.09, df=1, P=0.768, F<0.001).

Table 1. Study characteristics

| Study                  | Number | Weight | Dose       | Frequency | Duration |
|------------------------|--------|--------|------------|-----------|----------|
| Kaufman et al.10 (2001)| 50     | <1,000 g | 3 mg/kg    | Every 3 or 2 or 1 days | Weeks 1, 2, 3, 4, 5, 6 |
| Jannatdoust et al.11 (2015)| 43     | <1,250 g | 3 mg/kg    | Every 3 or 2 or 1 days | Weeks 1, 2, 3, 4, 5, 6 |
| Aghai et al.30 (2005)  | 140    | <1,000 g | 3 mg/kg    | Every 3 or 2 or 1 days | Weeks 1, 2, 3, 4, 5, 6 |
| Healy et al.12 (2008)  | 448    | <1,000 g | 3 mg/kg    | Every 3 or 2 or 1 days | Weeks 1, 2, 3, 4, 5, 6 |
| Healy et al.13 (2005)  | 240    | <1,000 g | 3 mg/kg    | Every 3 or 2 or 1 days | Weeks 1, 2, 3, 4, 5, 6 |
| Lee et al.14 (2016)    | 264    | <1,000 g | 3 mg/kg    | Twice weekly | 4 Weeks |
| Weitkamp et al.31 (2008) | 42   | <750 g   | 3 mg/kg    | Twice weekly | 4 Weeks |
| Rueda et al.32 (2010)  | 252    | <1,250 g | 3 mg/kg    | Every 2 days | 6 Weeks |
| Aydemir et al.33 (2010) | 93    | <1,500 g | 3 mg/kg    | Every 3 days | 30–45 Days |
| Manzoni et al.10 (2007a)| 104   | <1,500 g | 3 mg/kg    | Every 3 days/every 2 days | First 2 weeks/weeks 3–6 |
| Manzoni et al.11 (2007b)| 112   | <1,500 g | 6 mg/kg    | Every 3 days/every 2 days | First 2 weeks/weeks 3–6 |
| Bertini et al.34 (2005) | 136   | <1,500 g | 6 mg/kg    | Every 3 days/once daily | First week/weeks 2, 3, 4 |
| Manzoni et al.35 (2006) | 225   | <1,500 g | 6 mg/kg    | Every 3 days first week then every 2 days | Until 30th–45th day of life |
| Benjamin et al.36 (2014) | 188   | <750 g   | 6 mg/kg    | Twice weekly | 6 Weeks |
| Parikh et al.37 (2007)  | 60     | <1,500 g | 6 mg/kg    | Every 3 days/once daily | First week/weeks 2, 3, 4 |
| Kicklighter et al.38 (2001) | 53     | <1,500 g | 6 mg/kg    | Every 3 days/every days | Weeks 1/2, 3, 4 |
| Kirpal et al.14 (2016)  | 38     | <1,500 g | 6 mg/kg    | Every 2 or 1 days | Weeks 1/2, 3, 4 |

Table 2. Outcomes of prophylaxis regimens used in 16 studies were reviewed.
Table 2. Study outcomes of prophylactic fluconazole use in newborns

| Study                  | Study type | Outcome     | P value | Effect: no prophylaxis/prophylaxis n (%) |
|------------------------|------------|-------------|---------|------------------------------------------|
| Kaufman et al.\(^8\)  | RCT        | Colonization IC | 0.002  | 30/50 (60) 11/50 (22)                  |
|                        |            | Mortality   | 0.008  | 10/50 (20)                                |
|                        |            |             | 0.22   | 0 (0)                                     |
| Jannatdoust et al.\(^22\) (2015) | RCT        | Mortality   | 0.045  | 15/50 (30) 9/43 (20)                    |
| Aghai et al.\(^23\) (2006) | Cohort     | IC          | 0.006  | 9 (6.6)                                   |
|                        |            | Mortality   | 0.02   | 0 (0)                                     |
| Healy et al.\(^2\) (2008) | Cohort     | IC          | 0.003  | 15/206 (7.3) 9/448 (2)                   |
|                        |            | IC-associated mortality | 0.01  | 4/206 (2)                                |
| Healy et al.\(^4\) (2005) | Cohort     | IC          | 0.01   | 15/206 (7)                                |
|                        |            | IC-associated mortality | 0.04  | 5/240 (2)                                |
| Lee et al.\(^15\) (2016) | Cohort     | Colonization IC | 0.001  | 88/149 (59.1) 76/224 (33.9)              |
|                        |            | Mortality   | 0.80   | 7/159 (4.4)                               |
|                        |            | IC-associated mortality | 0.18  | 12/242 (5.0)                             |
|                        |            |             | 0.32   | 26/159 (16.4)                            |
|                        |            |             | 0.13   | 31/264 (11.7)                            |
|                        |            |             | 0.01   | 3/26 (1.1)                               |
|                        |            |             | >0.05  | 1/31 (3.2)                               |
| Weitkamp et al.\(^20\) (2008) | Cohort     | IC          | <0.05  | 9/44 (20)                                |
|                        |            | IC-associated mortality | -    | 0 (0)                                    |
|                        |            |             | 0.05   | 1/9 (11)                                 |
|                        |            |             | 0 (0)  | 9/44 (20)                                |
|                        |            |             | 0.05   | 11/42 (26)                               |
| Rueda et al.\(^26\) (2010) | Cohort     | IC          | <0.001 | 2/271 (7)                                |
|                        |            | IC-associated mortality | <0.05 | 3/252 (1.1)                             |
| Aydemir et al.\(^7\) (2010) | RCT        | Colonization IC | <0.001 | 39/91 (42.9) 10/93 (10.8)               |
|                        |            | Mortality   | <0.001 | 15/91 (16.5)                             |
|                        |            | IC-associated mortality | 0.64 | 3/93 (3.2)                              |
|                        |            |             | 0.42   | 8/93 (8.6)                               |
|                        |            |             |        | 11/91 (12.1)                             |
|                        |            |             |        | 1/93 (1.1)                               |
|                        |            |             |        | 3/91 (3.3)                               |

Table 2. Continued

| Study                  | Study type | Outcome     | P value | Effect: no prophylaxis/prophylaxis n (%) |
|------------------------|------------|-------------|---------|------------------------------------------|
| Manzoni et al.\(^24\) (2007a) | RCT        | Colonization IC | <0.001 | 31/106 (29.2) 8/104 (7.7)               |
|                        |            | Overall mortality | 1.000  | 14/106 (13.2)                             |
|                        |            |             | 4/106 (3.8) | 10/106 (9.4)   |
|                        |            |             | 9/104 (8.7)   |               |
| Manzoni et al.\(^25\) (2007b) | RCT        | Colonization IC | <0.001 | 31/106 (29.2) 11/112 (9.8)              |
|                        |            | Overall mortality | 0.81   | 14/106 (13.2)                             |
|                        |            |             | 3/112 (2.7)   | 10/106 (9.4)   |
|                        |            |             | 9/112 (8.0)    |               |
| Bertini et al.\(^26\) (2005) | Cohort     | IC          | 0.003  | 9/119 (7.6)                                |
|                        |            | Mortality   | 0.32   | 0 (0)                                     |
|                        |            |             | 15/119 (12.6) | 11/136 (8.1)    |
| Manzoni et al.\(^29\) (2006) | Cohort     | Colonization IC | <0.0001 | 105/240 (43.8) 54/225 (24.0)          |
|                        |            | Mortality   | 0.44   | 27/240 (11.2)                             |
|                        |            |             | 24/225 (10.6) |               |
| Benjamin Jr et al.\(^30\) (2014) | RCT        | IC <49 days | 0.02   | 16/188 (9)                                 |
|                        |            | IC before discharge | 0.02 | 6/173 (3)                                 |
|                        |            | Mortality <49 days | 0.98 | 19/188 (11)                                |
|                        |            | Neurodevelopment impairment | 0.84 | 8/173 (4)                                 |
|                        |            |             | 0.60   | 25/188 (14)                               |
|                        |            |             | 0.98   | 27/173 (14)                               |
|                        |            |             | 0.02   | 33/188 (19)                               |
|                        |            |             | 0.84   | 34/173 (18)                               |
|                        |            |             | 0.60   | 23/84 (27)                                |
|                        |            |             | 0.32   | 27/87 (31)                                |
| Parikh et al.\(^11\) (2007) | RCT        | Colonization IC | 0.001  | 30/60 (50)                                |
|                        |            | Mortality   | 1.000  | 11/60 (19)                                |
|                        |            |             | 15/60 (25) | 16/60 (26.7)    |
|                        |            |             | 17/60 (28) | 17/60 (28)       |
| Kicklighter et al.\(^9\) (2001) | RCT        | Colonization IC | 0.0005 | 23/5 (46)                               |
|                        |            | Mortality   | 0.131  | 8/53 (15.1)                               |
|                        |            |             | 2/50 (4)  | 3.7 (2/53)      |
|                        |            |             | 10/50 (20) | 5/53 (9.4)       |
| Kirpal et al.\(^31\) (2016) | RCT        | IC          | 0.04   | 16/37 (43.2)                             |
|                        |            | IC-associated mortality | 0.02 | 8/38 (21.0)                             |
|                        |            |             | 7/37 (18.9) | 1/38 (2.6)       |

IC, invasive candidiasis; RCT, randomized controlled trial.
2. Colonization and IC

The colonization of *Candida* spp. in different locations (endotracheal secretion, nasopharynx, periumbilical region, perineum, gastric aspirate, skin) was evaluated in 7 studies (Table 2). All showed significantly decreased colonization, and the meta-analysis showed that 6 mg fluconazole administered every 3 days in week 1 and every day in the following 3 weeks can prevent colonization in VLBW infants (Fig. 4) \( (P<0.001; \text{RR}, 0.350; 95\% \text{ CI}, 0.223–0.551) \). Additionally, IC was decreased significantly on day 10, but 3 studies in the prophylaxis group versus placebo or the no prophylaxis group reported data in different groups, most of which were not suitable for analysis or the assessed schedules ineffectively prevented IC in the meta-analysis (Fig. 5). The heterogeneity was not significant in these outcomes as depicted in Table 3 (group 4 for colonization: \( Q=0.06, \text{df}=1, \)).
P = 0.813, F < 0.001; group 4 for IC: Q = 0.01, df = 1, P = 0.813, F < 0.001). The funnel plot of standard error by log RR is shown in Fig. 6. The results of Egger regression test were t = 0.38, df = 7.0, and P = 0.71.

Discussion

Fungal invasion is a severe infection in VLBW infants that can result in mortality or otherwise affect quality of life. Prophylaxis with fluconazole both decreases mortality and decreases the incidence of neurodevelopmental impairments. Fluconazole prophylaxis is currently recommended for NICU-admitted infants with a ≥5% risk of an incidence of IC by many continental neonatology associations.33-37

The current meta-analysis showed that prophylaxis with fluconazole administered according to 1 of 7 surveyed schedules compared with no prophylaxis or placebo can significantly decrease the overall mortality rates of ELBW infants less than 1,000 g (RR, 0.780; 95% CI, 0.629-0.966). This effect was driven by the studies that used a dose of 3-mg/kg fluconazole every 3 days in weeks 1 and 2, every 2 days in weeks 3 and 4, and every day in weeks 5 and 6. IC-associated mortality also decreased significantly with fluconazole prophylaxis whenever
colonization prevented with a dose of 6-mg/kg fluconazole every 3 days in week 1 and every day in the following 3 weeks in 2 RCTs of VLBW infants weighing <1,500 g.

Some studies reported that prophylaxis with fluconazole can decrease IC and/or colonization without significantly affecting mortality.16-40

A candidiasis management guideline recommended intravenous or oral fluconazole prophylaxis in nurseries with high rates (>10%) of IC using 3–6 mg/kg twice weekly for 6 weeks in neonates with birth weights <1,000 g. Whenever this schedule with 3-mg/kg fluconazole assessed for preventing IC-associated mortality in current study had no significant effect \( (P=0.06) \).40 3-mg/kg fluconazole every 3 days in weeks 1 and 2, every 2 days in weeks 3 and 4, and every day in weeks 5 and 6 prevented IC-associated mortality \( (P=0.011) \). The differences in results between these studies and the current study can be attributed to differences in the studies assessed, the proposed endpoints, and the populations under study.

There were some limitations to the current study. First, the differences in study duration and medication administration might have created heterogeneity in the outcomes. Second, the endpoints differed between the current study and surveyed studies. Third, no antifungals other than fluconazole were investigated. Fourth, the subjects’ gestational ages and birth weights were not evaluated in this study. And finally, the following potential issues with the introduction of fluconazole prophylaxis to NICU patients should be considered: drug side effects, induction of resistance, and effect on mortality and IC.

Conflicts of interest
No potential conflict of interest relevant to this article was reported.

References

1. Benjamin DK Jr, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006;117:84-92.
2. IPDTC Working Group. Prevalence at birth of cleft lip with or without cleft palate: data from the International Perinatal Database of Typical Oral Clefts (IPDTC). Cleft Palate Craniofac J 2011;48:66-81.
3. Rao S, Ali U. Systemic fungal infections in neonates. J Postgrad Med 2003;51 Suppl 1:527-9.
4. Steinbach WJ. Epidemiology of invasive fungal infections in neonates and children. Clin Microbiol Infect 2010;16:1321-7.
5. Panmi M, Holland L, Butler G, Gacer S, Bliss JM. Candida parapsilosis is a significant neonatal pathogen: a systematic review and meta-analysis. Pediatr Infect Dis J 2013;32:e206-16.
6. Chow BD, Linden JR, Bliss JM. Candida parapsilosis and the neonate: epidemiology, virulence and host defense in a unique patient setting. Expert Rev Antimicrob Infect Ther 2012;10:935-46.
7. Arsenault AB, Bliss JM. Neonatal candidiasis: new insights into an old problem at a unique host-pathogen interface. Curr Fungal Infect Rep 2015;9:246-52.
8. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001;345:1660-6.
9. Kicklighter SD, Springer SC, Cox T, Hulsey TC, Turner RB. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics 2001;107:293-8.
10. Manzoni P, Stolfi I, Pugini L, Decembrino L, Magnani C, Vetrano G, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007;356:2483-95.
11. Parikh TB, Nanavati RN, Patankar CV, Rao S, Bisure K, Udani RH, et al. Fluconazole prophylaxis against fungal colonization and invasive fungal infection in very low birth weight infants. Indian Pediatr 2007;44:830-7.
12. Healy CM, Campbell JR, Zaccaria E, Baker CJ. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics 2008;121:703-10.
13. Kaufman DA, Cuff AL, Wanstad JB, Boyle R, Gurka MJ, Grossman LB, et al. Fluconazole prophylaxis in extremely low birth weight infants and neurodevelopmental outcomes and quality of life at 8 to 10 years of age. J Pediatr 2011;158:759-65.e1.
14. Friedman S, Richardson SE, Jacobs SE, O'Brien K. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J 2000;19:499-504.
15. Lee J, Kim HS, Shin SH, Choi CW, Kim EK, Choi EH, et al. Efficacy and safety of fluconazole prophylaxis in extremely low birth weight infants: multicenter pre-post cohort study. BMC Pediatr 2016;16:67.
16. Che D, Zhou H, Li T, Wu B. Duration and intensity of fluconazole for prophylaxis in preterm neonates: a meta-analysis of randomized controlled trials. BMC Pediatr 2016;16:312.
17. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Grossman LB. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J Pediatr 2005;147:172-9.
18. Leonard LE, Tonin FS, Ferreira VL, Tavares da Silva Pentecado S, de Aratijo Motta F, Pontarolo R. Fluconazole doses used for prophylaxis of invasive fungal infection in neonatal intensive care units: a network meta-analysis. J Pediatr 2017;185:129-35.e6.
19. Dorland WAM. Dorland’s illustrated medical dictionary. 32nd ed. Philadelphia (PA): Elsevier Health Sciences; 2011.
20. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
21. Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers'
to authors’ assessments. BMC Med Res Methodol 2014;14:45.

22. Jannatdoust A, Imani V. The effect of prophylactic intravenous fluconazole.

23. Aghai ZH, Muddahuru M, Nakhta TA, Amendolia B, Longo D, Kemble N, et al. Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. J Perinatol 2006;26:e550-5.

24. Healy CM, Baker CJ, Zaccaria E, Campbell JR. Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J Pediatr 2005;147:166-71.

25. Weitkamp JH, Ozdas A, LaFleur B, Potts AL. Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure. J Perinatol 2008;28:405-11.

26. Rueda K, Moreno MT, Espinosa M, Sáez-Llorens X. Impact of routine fluconazole prophylaxis for premature infants with birth weights of less than 1250 grams in a developing country. Pediatr Infect Dis J 2010;29:1050-2.

27. Aydemir C, Oguz SS, Dizdar EA, Akar M, Sarikabadayi YU, Saygan S, et al. Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants. Arch Dis Child Fetal Neonatal Ed 2011;96:F164-8.

28. Blyth CC, Barzi F, Hale K, Isaacs D. Chemoprophylaxis of neonatal fungal infections in very low birthweight infants: efficacy and safety of fluconazole and nystatin. J Paediatr Child Health 2012;48:846-51.

29. Benjamin DK Jr, Stoll BJ, Gantz MG, Walsh MC, Sánchez PJ, Das A, et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics 2010;126:e865-73.

30. Cleminson J, Austin N, McGuire W. Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev 2015;2015:CD003850.

31. Santolaya ME, Alvarado Matute T, de Queiroz Telles F, Colombo AL, Zurita J, et al. Recommendations for the management of candidemia in neonates in Latin America. Latin America Invasive Mycosis Network. Rev Iberoam Micol 2013;30:158-70.

32. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.

33. How to cite this article: Anaraki MR, Nouri-Vaskeh M, Oskoei SA. Fluconazole prophylaxis against invasive candidiasis in very low and extremely low birth weight preterm neonates: a systematic review and meta-analysis. Clin Exp Pediatr 2021;64:172-9. https://doi.org/10.3345/cep.2019.01431